Immix Biopharma Awarded European Union Orphan Drug Designation For NXC-201 In Multiple Myeloma

+3.13% Pre

IMMIX BIOPHARMA, INC.

IMMX

1.65

+3.13%

0.00% Pre

European Orphan Drug Designation ("ODD") qualifies NXC-201 for:

10 years of market exclusivity once authorized in the EU
Access to the EU centralized authorization procedure
- Reduced fees for: EU protocol assistance, marketing authorization applications, inspections before authorization, applications for changes to marketing authorizations made after approval, and reduced annual fees

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.